16 Toulany M, Schickfluss T A, Eicheler W, et al. Impact of oncogenic K-Ras on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res, 2011, 13: R28
[2]
17 Minjgee M, Toulany M, Kehlbach R, et al. K-Ras(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys, 2011, 81: 1506-1514
[3]
18 Campbell P M, Groehler A L, Lee K M, et al. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res, 2007, 67: 2098-2106
[4]
19 Banerjee J, Al-Wadei H A, Schuller H M. Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts. Eur J Cancer, 2013, 49: 1152-1158
[5]
20 Liu S, Wang J, Niu W, et al. The β6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett, 2013, 328: 325-334
[6]
21 Jeong E K, Lee S Y, Jeon H M, et al. Role of extracellular signal-regulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells. Int J Oncol, 2010, 37: 655-661
[7]
22 GaRassino M C, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol, 2011, 22: 235-237
[8]
1 Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-Ras genes. Cell, 1988, 53: 549-554
[9]
2 Hanlon L, Avila J L, Demarest R M, et al. Notch1 functions as a tumor suppressor in a model of K-Ras-induced pancreatic ductal adenocarcinoma. Cancer Res, 2010, 70: 4280-4286
[10]
3 Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-Ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410: 1111-1116
[11]
4 Heidorn S J, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 2010, 140: 209-221
[12]
5 Martin T D, Samuel J C, Routh E D, et al. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res, 2011, 71: 206-215
[13]
6 Shen L, Nishioka T, Guo J, et al. Geminin functions downstream of p53 in K-Ras-induced gene amplification of dihydrofolate reductase. Cancer Res, 2012, 72: 6153-6162
[14]
7 Yoon J, Koo K H, Choi K Y. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res, 2011, 71: 445-453
[15]
8 Zhao L, Vogt P K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA, 2008, 105: 2652-2657
[16]
9 Neuzillet C, Hammel P, TijeRas-Raballand A, et al. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev, 2013, 32: 147-162
[17]
10 Baynes R D, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther, 2009, 16: 554--561
[18]
11 Tsao M S, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol, 2007, 25: 5240-5247
[19]
12 Capelletti M W X, Gu S L, Graziano, et al. Impack of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. J Clin Oncol, 2010, 28: 7008
[20]
13 Pickard M, Sherrington P, Brett M, et al. Mutation in the K-Ras gene at codon 12 does not correlate with disease progression in colorectal carcinoma patients treated with 5-FU/folinic acid biomodulated chemotherapy. Int J Oncol, 1996, 9: 1301-1306
[21]
14 Rosty C, Chazal M, Etienne M C, et al. Determination of microsatellite instability, p53 and K-Ras mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer, 2001, 95: 162-167
[22]
15 Xiao J, Chen L W, Chen J X, et al. Construction of a recombinant eukaryotic expression plasmid containing human PDLIM2 gene and its biological activity. Plasmid, 2011, 66: 106-111
